Healthtree, Inc.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
4
Ending by 2030
Jan 2028
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
No maintenance fee falls due on this company's record before Nov 16, 2027.
Recent changes
- 1 term has ended since Aug 18, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 5 of 5
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,919,079 | Cancer Immunotherapy Compositions and Methods of Use In force · High confidence | In force | High confidence | |
| US 8,580,247 | PS-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 7,901,902 | Methods and Compositions for Identifying a Cellular Immune Response Against Prostate Cancer In force · High confidence | In force | High confidence | |
| US 9,669,081 | Methods and Compositions for Treating Prostate Cancer or Inducing a Humoral Immune Response Against Prostate Cancer In force · High confidence | In force | High confidence | |
| US 9,770,467 | Compositions and Methods for Cancer Immunotherapy In force · High confidence | In force | High confidence |
Also on record, not counted in the 5: 1 lapsed for an unpaid fee · 2 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.